Webcast: Anticipating and Resolving Potential Licensing and Collaboration Disputes Before They Arise
Join Gibson Dunn lawyers for the first recorded session of a three-part series following a single life sciences collaboration and licensing dispute across its full lifecycle to explore how contract language, forum selection, and science shape leverage, timing, proof, and outcomes.
The series opens where disputes begin: the agreement itself. This session examines how licensing and collaboration terms create or avoid conflict, where leverage develops as the parties’ relationship evolves, and how parties can resolve emerging disagreements—ideally preserving the business relationship—before anyone reaches the courthouse or arbitration table.
PANELISTS:
Ryan Murr is widely recognized as one of the nation’s leading corporate lawyers in the life sciences industry. Over his career, he has advised on more than 500 transactions representing over $100 billion in aggregate transaction value, spanning mergers and acquisitions, capital markets, royalty monetizations, and structured financings, reflecting a combination of scale and breadth matched by few practices in the United States. Ryan has more than 25 years of experience representing public and private life sciences companies and investors in connection with securities offerings and business combination transactions. Ryan serves as principal outside counsel for publicly traded companies and private venture-backed companies, advising management teams and boards of directors on corporate law matters, SEC reporting, corporate governance, and M&A transactions.
Mary Beth Maloney is a first-chair trial lawyer for public companies, their boards, and senior executives in their highest-stakes federal and state court litigation, securities matters, government enforcement actions, and complex commercial disputes, with a particular focus on healthcare, life sciences, and financial services. She is regularly retained as lead trial counsel when public companies face existential threats—from regulators and watchdog organizations, in securities class actions and SEC enforcement matters, and in bet-the-company commercial disputes.
Karen Spindler is a corporate partner in the San Francisco office of Gibson Dunn where her practice focuses on advising life sciences companies and investors on a variety of intellectual property transactions. Karen represents the full spectrum of companies in the life sciences sector, including companies operating in the areas of pharmaceuticals, biologics, diagnostics, and medical devices. Karen has considerable experience structuring complex strategic collaboration and partnering transactions, including co-development, co-commercialization and joint venture arrangements, and advising on manufacturing and supply agreements, services arrangements, and academic licenses.